胸腺肽α1在高危复发肺癌术后的维持治疗中的临床观察

Clinical Observation of Immunization Maintenance Treatment with Thymosin Alpha-1 (Tα1) on Postoperative Lung Cancer with High Risk Recurrence

摘要: 目的：观察高危复发肺癌术后化疗后，予胸腺肽α1维持治疗，对无病生存期的影响。方法：选取我科2011~2012年有高危复发风险的肺癌术后病人，分成两组，一组化疗后予胸腺肽α1 1.6 mg BIW维持治疗>6月，一组化疗后未行胸腺肽α1维持治疗的病人，比较两组无病生存期。结果：予胸腺肽α1维持治疗组的无病生存期较未行免疫维持治疗组稍延长，但P = 0.385，差异无统计学意义。如果排除脑转移后，予胸腺肽α1组无病生存期明显延长，P = 0.039。结论：建议肺癌术后，高危复发病人，常规辅助化疗后，常规予胸腺肽α1维持治疗。

Abstract: Objective: To investigate the clinical benefit of immunization maintenance treatment with Tα1 on postoperative lung cancer with high risk recurrence. Methods: Patients of postoperative lung cancer with high risk recurrence were chosen between 2011-2012 and divided into two groups: Tα1 maintenance treatment group after chemotherapy, not with Tα1 maintenance treatment group after chemotherapy. Tα1 is used twice a week at least 6 months Median time to disease progression (TTP) were analyzed by Kaplan-Meier method. Results: The Tα1 group prolong TTP, but P = 0.385. IF brain metastases are rejected. The Tα1 group prolongs TTP obviously, P = 0.039. Conclusion: Immunization maintenance treatment with Tα1 is recommended for lung cancer with high risk recurrence.